Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCU410 for Geographic Atrophy Secondary to Dry AMD
NCT07770828Phase 3Recruiting
- Sponsor
- Ocugen
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of OCU410 in age-related macular degeneration (AMD) (2 arms), sponsored by Ocugen. Primary endpoint: Rate of change (slope) of square root-transformed GA lesion area at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
OCU410
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07770828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770828.